In recent years, chimeric antigen receptor T-cell therapy has emerged out to be one of the most promising cancer therapies.
China Emerging CAR T Cell Therapy Research Hub After USA With More Than 200 Clinical Trials Says Kuick Research
Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
- Global & Regional Market Insight: Current & Market Forecast 2028
- Approved CAR T Cell Therapies Sales Forecast Till 2028
- Emerging In Vivo Induced CAR T Cell Therapies
- CAR T Cell Therapy Manufacturing Cost Analysis
- CAR T Cell Therapy Approval & Reimbursement Scenario By Country
- Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
- Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
- CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Download Report: https://www.kuickresearch.com/report-car-t-cell-therapy-market
In recent years, chimeric antigen receptor T-cell therapy has emerged out to be one of the most promising cancer therapies. The breakthrough approval of first CAR T-cell therapy in 2017 has gained momentum among pharmaceutical companies. To date, globally there are 7 approved CAR T-cell therapy products in the market which are indicated for wide range of hematological malignancies. The introduction of CAR T-cell therapy in the market has shown promising response among cancer patients. This has surged the further research and development activities in this therapeutic drug class.
Currently, more than 600 clinical trials are ongoing in global CAR T cell therapies market which is showing positive results in the market. For instance, Caribou Bioscience has developed CB-010, which is allogeneic CAR T cell therapy. The initial results from the trial in non-Hodgkin lymphoma patients demonstrated that the drug has significantly improve the overall survival rate and complete response rate. Moreover, the investigational therapy was well-tolerated and is associated with side effects which are routinely observed with other CAR T cell therapies.
Regionally, US is one of the most developed market for CAR T cell therapy owing to the availability of wide range of therapeutic drugs and their robust sales in the region. The rising government initiatives and rapid launch of new products in the region also propels the growth of this region. For instance recently in 2022, US FDA has granted approval to Carvykti ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma. The initial uptake of novel CAR T cell therapies in the region is another factor aiding in dominance of this region.
In contrast to US, China is still evolving in CAR T cell therapy market. Currently, two CAR T cell therapies have been approved in China in comparison to 7 approved globally. In June, 2021 Kite, a Gilead Company, announced that Fosun Kite Biotechnolog, a joint venture between Kite and Shanghai Fosun Pharmaceutical (Group) has received approval from the China National Medical Products Administration (NMPA) for axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL). In September, 2021 Relma-cel marks China’s second approved CAR T cell therapy products. The drug is developed by JW Therpeutics and is indicated for the treatment of large B cell lymphoma.
Although China has approved only two CAR T cell therapies, it is analyzed that the ongoing trend in the market are coping up to meet with the rising other markets. Several domestic players in China are investing huge amount in development of CAR T cell therapy products. Carsgen Therapeutics has developed a robust pipeline of next generation CAR T cell therapies which are ongoing clinical trials in China. The major CAR T cell therapy products developed by the company are CT053, CTO041, CT011 CT032, CT017, and other which are being evaluated against wide range of solid as well as hematological malignancies. CT053 is leading product which is upgraded fully human, autologous BCMA CAR T cell for the management of multiple myeloma. The candidate is undergoing phase-II clinical trial in China. CT053 has received Breakthrough Therapy Designation from NMPA in 2020 and the company plans to submit for marketing approval to NMPA in first half of 2022.
As per our report findings, the global CAR T cell therapy market is expected to surpass US$ 15 Billion by 2028. The major factors which are propelling the growth of market include surge in prevalence of various hematological malignancies. Apart from this, ongoing clinical trials are also evaluating the role of these drugs in other solid tumors, and other non-oncological conditions which will also drive its market.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366